ssNPA Device for Upper Airway Obstruction
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the effectiveness of a new device, the Self-Supporting Nasopharyngeal Airway (ssNPA), for children with obstructive sleep apnea due to Hypotonic Upper Airway Obstruction (HUAO). The researchers aim to determine if this device can alleviate common symptoms such as snoring, daytime sleepiness, or hyperactivity. Participants will either use the ssNPA device or continue with their usual care while awaiting another treatment option. Children who have had their tonsils removed or cannot undergo this surgery, yet still experience significant sleep issues, may be suitable candidates. As an unphased trial, this study provides a unique opportunity for children to potentially benefit from an innovative treatment option.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What prior data suggests that the ssNPA device is safe for treating upper airway obstruction in children?
Research shows that the Self-Supporting Nasopharyngeal Airway (ssNPA) device is generally safe for treating breathing problems in people with low muscle tone. In earlier studies, patients using the ssNPA device did not report any serious side effects. Some individuals might worry about comfort, as it may feel strange initially. However, no major safety issues have emerged.
The device helps keep the airway open during sleep and is especially aimed at children with obstructive sleep apnea, a condition where breathing stops and starts during sleep. Although data is limited, available research suggests that most patients can use the ssNPA device without significant problems.
Overall, the ssNPA device appears to be a safe option, but discussing any concerns with a healthcare provider is important. They can offer advice based on individual needs and conditions.12345Why are researchers excited about this trial?
The Self-Supporting Nasopharyngeal Airway (ssNPA) is unique because it offers an innovative approach to managing upper airway obstruction, differing significantly from standard treatments like positive airway pressure (PAP) devices. Unlike traditional options that rely on external machines to maintain airflow, the ssNPA is a self-supporting device, which means it physically keeps the airway open without the need for external power or machines. Researchers are excited about this treatment because it could provide a more convenient and less cumbersome solution for patients, potentially improving compliance and comfort. Furthermore, ssNPA’s simple design allows for easier use, making it particularly promising for individuals who struggle with complex equipment.
What evidence suggests that the ssNPA device is effective for obstructive sleep apnea?
Research shows that the Self-Supporting Nasopharyngeal Airway (ssNPA) device, which participants in this trial may receive, can help treat obstructive sleep apnea (OSA), a condition where the airway blocks during sleep. Studies have found that the ssNPA device can lower the Apnea/Hypopnea Index (AHI), which measures the severity of sleep apnea. Patients report that the device is comfortable and easy to use, making it a good option for those with weakened upper airway muscles. The ssNPA could serve as an alternative to more invasive treatments like surgery or a tracheostomy. Although not widely used yet, early research suggests it can be a useful tool for managing airway blockage.12467
Who Is on the Research Team?
David Zopf, MD
Principal Investigator
The University of Wisconsin
Louise O'Brien, PhD
Principal Investigator
University of Michigan
Are You a Good Fit for This Trial?
This trial is for children with Hypotonic Upper Airway Obstruction and obstructive sleep apnea who've had a tonsillectomy or can't have one. They must show symptoms like snoring, daytime sleepiness, or hyperactivity. Kids with severe breathing issues during sleep, bleeding disorders, certain airway collapses, active COVID-19 infection, or those on blood thinners cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Waitlist Control
Participants are placed on a waitlist for positive airway pressure (PAP) for 8 weeks
Treatment
Participants receive the Self-Supporting Nasopharyngeal Airway (ssNPA) device
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Self-Supporting Nasopharyngeal Airway (ssNPA)
Self-Supporting Nasopharyngeal Airway (ssNPA) is already approved in United States, European Union for the following indications:
- Obstructive Sleep Apnea in children with Hypotonic Upper Airway Obstruction
- Upper Airway Obstruction in children with hypotonia
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Michigan
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator